OUR NEW PROFILE IS: (NASDAQ: COSM)
COSM just posted $3.7 million in profits for the first six months of 2022
MASSIVE SHIFT TO PREVENTIVE HEALTHCARE COULD PROPEL THE GLOBAL NUTRACEUTICALS MARKET TO $1 TRILLION BY 2030
Yahoo has the Market cap on COSM at just 9.6M
The Company Just Achieved Annual Revenues of $56 Million and Reported a 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022
We have another profile for today’s session that we want you to take a look at.
This one has a number of catalysts worth looking at for today.
It trades on a major exchange and is sitting under .50 and in a profitable financial situation.
I want you to pull up COSM immediately.
Take a look at some of the catalysts in play:
Amazon: Cosmos Health Inc. (COSM) just launched its “Sky Premium Life” nutritional supplement products on Amazon in the United States (25), tapping into the 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)
Booming Market: It is estimated that 77% of Americans use dietary supplements (27)while the U.S. nutraceutical market is expected to hit $138.0 billion by 2027(25) and the global nutraceuticals market is expected to reach $1 trillion by 2030. (23)
Gross Profits: Cosmos Health Inc. (COSM) just reported a 202.42% increase in adjusted EBITDA with gross profits increasing by 23.0% to $3.7 million for the six months ended June 30, 2022.(26)
Value: Cosmos Health Inc. (COSM) is a very small company with a market cap just under $9.3 million according to Yahoo finance. (31) Not bad for a company that just posted $3.7 million in profits for the first six months of 2022. (26)
Upside Potential: The company was listed on the NASDAQ on February 28th, 2022 when it reached an intraday high of $3.92 and closed around $.36 on September 2nd, 2022 according to Barchart.com. That means Cosmos Health Inc. (COSM) is approximately 988% off its 52-week high. Can you say potential upside?.
Couple all of this with a tiny market cap and strong financial news, this one has potential moving forward.
The rising demand for dietary supplements and functional foods is expected to be a major driving force in the preventive healthcare market. (19)
In addition, a positive outlook toward medical nutrition, given its growing use in the treatment of cardiovascular disorders and malnutrition, is likely to boost the growth of the nutraceuticals market in the coming years. (19)
The rising geriatric population, rising healthcare costs, changing lifestyles, food innovation, and expectations regarding higher prices will propel the growth of the nutraceuticals market in the upcoming years. (19)
Consumers have a very positive attitude toward nutraceuticals, nutritional supplements, and functional foods – owing to the additional health and wellness benefits that these products provide, driving the market’s growth. (19)
During the pandemic period, demand for nutraceuticals expanded globally due to the flexibility of storage choices, the need for combination formulations with various benefits, increasing consumer education levels, educated consumers, and the growth in health concerns among informed consumers.(19)
Moreover, rising healthcare costs, combined with an aging global population, are expected to drive the global nutraceuticals industry’s growth over the next decade. (19)
One company that could benefit from the massive shift to Nutraceuticals is Cosmos Health Inc. (NASDAQ: COSM). (18)
Cosmos Health Inc. is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The company is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” (21)
Cosmos Health Inc. (NASDAQ: COSM) offers broad exposure to the pharmaceutical sector as well, through a broad line of branded generics and over-the-counter (OTC) medications. (21)
In addition, Cosmos Health Inc. is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK serving retail pharmacies and wholesale distributors.
The company is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. (21)
Cosmos Health Inc. (NASDAQ: COSM) specifically focuses on the following business segments:
The Global Nutraceuticals Market Expected To Reach $1 Trillion by 2030 (23)
Cosmos Health Inc. (NASDAQ: COSM) could potentially be well positioned for this unprecedented opportunity in the nutraceuticals market.
Market Overview: Nutraceuticals is a comprehensive umbrella term which is used to label any product acquired from food origin with additional health advantages over and above the basic nutritious value available in foods. (23)
Nutraceuticals can be regarded as non-precise biological remedies used to boost general health, regulate indications and avert malignant developments. (23)
Nutraceuticals can be segmented on the foundation of their natural basis, pharmacological circumstances, as well as chemical structure of the products. Most often nutraceuticals are organized in the following classes: functional food, dietary supplements, pharmaceuticals, and medicinal food. (23)
According to a report from Precedence Research, crucial factors accountable for nutraceutical market growth are: (23)
Cosmos Health Inc. (COSM) Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States (25)
In August 2022, Cosmos Health Inc. launched the first of its “Sky Premium Life” products on Amazon in the United States. The company targets having all 85 product SKUs listed on Amazon by year end. (25)
“We are excited to officially launch our Sky Premium Life products on Amazon in the United States,” stated Greg Siokas, Chief Executive Officer of Cosmos Health. (25)
To view the full Sky Premium Life product line click here.
Amazon News: This could prove to be a complete game changer for Cosmos Health Inc.(COSM) as the platform has 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)
Cosmos Health Inc. (COSM) Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 (26)
For the fifth year in a row, US News & World Report in January of 2022 ranked the Mediterranean diet No. 1 in multiple categories, including best for heart health, best for diabetes and best overall diet for weight loss. (12)
Even the prestigious Mayo clinic has declared the diet heart healthy (14) and for good reason…
The Mediterranean Basin has a very unique climate found in only a few places in the world. It is sunny, hot, and dry in the summer, with cold and wet winters.(15) That’s what makes the herbs, plants and pretty much everything from the region so in-demand.
On April 12, 2022, Sky Premium Life, Cosmos’ proprietary luxury nutritional supplement product line, launched Mediterranation, a new premium line of nutritional supplements. That can leverage the awareness of the extremely popular Mediterranean diet with a full line of supplements. (13)
High demand. High quality. Excellent revenue potential.
Cosmos Health Inc. (COSM) Invests in Advanced Technologies to Expand Productivity(11)
A few months back, Cosmos made a HUGE announcement in regards to installing a “State-of-the-Art” automated fulfillment system at their logistics center in Greece.
The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates.
The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes.
Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,
CosmoFarm, headquartered in Athens, Greece is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. CosmoFarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1,130 pharmacies.
Now, to the Bread and Butter: Cosmos Health Inc. (COSM) Has a Comprehensive Strategy
Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.
Cosmos Health Inc. (COSM) is Also Very Well Known for the Following 3 Subsidiaries Under its Belt: (8)
Sky Pharm SA:
Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher.
Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, The United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area.
Could Cosmos Health Inc. (COSM) Climb 988% Back To $3.92?
Taking a look at the chart above (from StockCharts.com) and observing the technical analysis you can clearly see the following moving averages:
– 50 day moving average at $.38
– 120 day moving average at $.94
– 20 day exponential moving average $.36 (key line of potential resistance)
But what you don’t see – is what this actually means in dollars and cents.
Meaning, that if Cosmos Health Inc. (COSM) trends above its first line of resistance at the $.36 range… then the next line of potential resistance may be all the way at $.94, which, if reached, would represent an approximate 161% potential move.
Furthermore, if Cosmos Health Inc. (COSM) were to climb back to $3.92 from $.36 (closing price as of 9/2/22), it would represent an approximate 988% move.
Now, I’m not saying that Cosmos Health Inc. (COSM) is going to reach those levels today, tomorrow, or next week, but you need to be aware of its potential upside from current trading levels.
You see, from a technical analysis perspective, Cosmos Health Inc. (COSM) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”
…And by definition, the “Descending Triangle Breakout Strategy,” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (31)
This strategy uses a very simple combination of trading volumes and asserting the trend, which can be used to capture short term vertical moves.(31)
The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (31)
Massive Shift To Preventive Healthcare Could Propel The Global Nutraceuticals Market To $1 Trillion By 2030. (17)
One company that could be extremely well positioned for this unprecedented opportunity is Cosmos Health Inc. (NASDAQ: COSM)…(18)
Cosmos Health to Launch Sky Premium Life Nutritional Supplement Products in Germany and Austria via Amazon and Ebay
Cosmos Health Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States
Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022
Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company’s Evolution into an Innovative Global Healthcare Group, Driven by One Purpose: Improving People’s Lives
Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board
Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928; Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands
Cosmos Holdings Subsidiary Granted Full Membership in PAGB, A UK-based Consumer Healthcare Association
Cosmos Holdings Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board
Cosmos Holdings to Acquire LIFE NLB Portfolio of Bone Health Products that Target the Gastrointestinal Microbiome
Cosmos Holdings Announces Strategic R&D Partnership with Cloudpharm P.C. to Study the Human Gastrointestinal Microbiome and Launch Related Products Targeting on Obesity and Other Gut-Related Disorders
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon in the United States
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon Canada
Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board’s Audit Committee
Mr. Grigorios Siokas has over 15 years’ experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly-owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark.
Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over € 78 million); Thrakis Pharmaceuticals, (annual sales of over € 20 million); Thessalias Pharmaceuticals, (annual sales of over € 18 million); and ZED Pharma SA, (annual sales of over € 35 million).
During the 1990s, Mr. Siokas founded and operated a marble wholesale import – export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers.
Mr. Grigorios Siokas has Bachelor’s Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master’s in management and finance from the University of Stuttgart and the University of Tuebigen, Germany and has served in the Greek Army.
Dimitrios Goulielmos joined us as CEO and Director on September 27, 2013. Since January 1991, he has been the principal attorney at the law firm of Goulielmos D. & Partners. He contributes to the Board the benefits of his legal, academic, and business background.
Mr. Goulielmos is a fourth generation attorney. He received his law degree with Excellency from the Aristotle University of Thessaloniki in 1988. He did post graduate studies for International transactions and Company law at Paris, France and at the LSE of London, England.
In 2004 he was elected Vice-president of EUROPECHE, the organization that was established by the European Committee for the consultation and proposal of solutions in the sector of Community Fishery.
The same year he was also elected as National representative of Hellas in the MEDISAMAK, the organization responsible for all Mediterranean countries, in the sector of Fishery.
In year 2007 he was re-elected as Vice-president of EUROPECHE. He is a member of the social dialogue group of ACFA, of EU on labor affairs.
He is an honorary lifetime member of International Who’s Who Historical Society.
Mr. Goulielmos has extensive experience in law, international deals, mergers, acquisitions, negotiations, international application of licenses, and real estate management which he will contribute to the Board.
Mr. Demetrios G. Demetriades was elected as Secretary and Director of the Company.
Since January 2003, Mr. Demetriades, age 48, has been Director of Highlander Spring Trading Ltd, a trading company.
From November 2000 to December 2002 he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange.
From January 1995 to November 2000 he was Supervising Officer of Laiki Factors Ltd, a financing company.
As a member of the board, Mr. Demetriades contributes the benefits of his trading, executive leadership and management experience.